An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease

Arzu Öztürk Kesebir

doi:10.17776/csj.1860936

An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease

Abstract

Monoamine oxidase-B (MAO-B) is a key enzyme involved in dopamine metabolism and plays a central role in the pathogenesis of Parkinson’s disease, making it an important pharmacological target. In this study, an integrated early-stage inhibitor discovery strategy was applied by combining ligand-based similarity screening with computational analyses to identify novel MAO-B inhibitors. Using the SwissSimilarity platform, previously reported MAO-B inhibitors were used as reference compounds, and structurally related candidates were selected and evaluated for their predicted binding potential against MAO-B. Among the screened series, compound 9 exhibited the most favorable predicted binding affinity. To assess its drug-likeness and developability, comprehensive ADMET predictions were performed, revealing an overall acceptable pharmacokinetic and toxicological profile. To clarify the molecular basis of inhibition, molecular docking analyses were carried out, demonstrating that compound 9 adopts a favorable binding orientation within the MAO-B active site and establishes key interactions with catalytically important residues. To further validate binding stability, a 100 ns molecular dynamics simulation was conducted. The MAO-B–compound 9 complex preserved its structural integrity throughout the simulation, maintaining active-site alignment and stable intermolecular interactions. Detailed analyses of RMSD, RMSF, radius of gyration, hydrogen bond occupancy, and energy profiles consistently indicated that ligand binding did not induce significant conformational disturbances in the enzyme structure. In conclusion, this study demonstrates that the integrated use of SwissSimilarity-guided compound selection and in silico modeling provides an effective strategy for the early identification of MAO-B-targeted inhibitors. Compound 9 therefore warrants further computational and experimental evaluation.

Keywords

Inhibition, Molecular dynamics simulation, Monoamine oxidase-B (MAO-B), Parkinson's disease, SwissSimilarity

References

Sekar, P. K. C., Thomas, S. M., & Veerabathiran, R. (2024). An overview of the role of monoamine oxidase-B in Parkinson’s disease: implications for neurodegeneration and therapy. Exploration of Neuroprotective Therapy, 4, 308–318. https://doi.org/10.37349/ent.2024.00085
Jost, W. H. (2022). A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease. Journal of Neural Transmission, 129(5–6), 723–736. https://doi.org/10.1007/s00702-022-02465-w
Stocchi, F., Antonini, A., Berg, D., Bergmans, B., Jost, W., Katzenschlager, R., Kulisevsky, J., Odin, P., Valldeoriola, F., & Chaudhuri, K. R. (2022). Safinamide in the treatment pathway of Parkinson’s disease: a European Delphi consensus. npj Parkinson’s Disease, 8, Article 17. https://doi.org/10.1038/s41531-022-00277-z
Morales Casado, M. I., & López Ariztegui, N. (2025). Use of safinamide for treatment of Parkinson disease: real-world data from Spain. Drugs in Context, 14, Article 2025-5-5. https://doi.org/10.7573/dic.2025-5-5
Alborghetti, M., Bianchini, E., De Carolis, L., Galli, S., Pontieri, F. E., & Rinaldi, D. (2024). Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regeneration Research, 19(1), 16–21. https://doi.org/10.4103/1673-5374.375299
Asano, H., Tian, Y. S., Hatabu, A., Takagi, T., Ueda, M., & Ikeda, K. (2023). Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Scientific Reports, 13, Article 19272. https://doi.org/10.1038/s41598-023-44142-2
Zoete, V., Daina, A., Bovigny, C., & Michielin, O. (2016). SwissSimilarity: A web tool for low to ultra-high throughput ligand-based virtual screening. Journal of Chemical Information and Modeling, 56(8), 1399–1404. https://doi.org/10.1021/acs.jcim.6b00174
Salmaso, V., & Moro, S. (2018). Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. Frontiers in Pharmacology, 9, 923. https://doi.org/10.3389/fphar.2018.00923
Rogers, D., & Hahn, M. (2010). Extended-connectivity fingerprints. Journal of Chemical Information and Modeling, 50(5), 742–754. https://doi.org/10.1021/ci100050t
PerkinElmer Informatics, Inc. (2017). ChemDraw Professional 17.1 [Computer software]. PerkinElmer Informatics.

O’Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, Article 33. https://doi.org/10.1186/1758-2946-3-33
Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4, Article 17. https://doi.org/10.1186/1758-2946-4-17
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D. E., & Mattevi, A. (2002). Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nature Structural Biology, 9(1), 22–26. https://doi.org/10.1038/nsb732
Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry, 19(14), 1639–1662. https://doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
Martin, T. (2016). User’s guide for TEST (Version 4.2): Toxicity Estimation Software Tool—A program to estimate toxicity from molecular structure (EPA/600/R-16/058). U.S. Environmental Protection Agency.
Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
Zoete, V., Cuendet, M. A., Grosdidier, A., & Michielin, O. (2011). SwissParam: A fast force field generation tool for small organic molecules. Journal of Computational Chemistry, 32(11), 2359–2368. https://doi.org/10.1002/jcc.21816
Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. The Journal of Chemical Physics, 126(1), 014101. https://doi.org/10.1063/1.2408420
Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/10.1063/1.328693
Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577–8593. https://doi.org/10.1063/1.470117
Hess, B. (2008). P-LINCS: A parallel linear constraint solver for molecular simulation. Journal of Chemical Theory and Computation, 4(1), 116–122. https://doi.org/10.1021/ct700200b
Grace Development Team. (2015). Grace User’s Guide (Version 5.1.25).
Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. https://doi.org/10.1016/0263-7855(96)00018-5
Warren, G. L., Andrews, C. W., Capelli, A. M., Clarke, B., LaLonde, J., Lambert, M. H., Lindvall, M., Nevins, N., Semus, S. F., Senger, S., Tedesco, G., Wall, I. D., Woolven, J. M., Peishoff, C. E., & Head, M. S. (2006). A critical assessment of docking programs and scoring functions. Journal of Medicinal Chemistry, 49(20), 5912–5931. https://doi.org/10.1021/jm050362n
Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, Article 42717. https://doi.org/10.1038/srep42717
Daina, A., & Zoete, V. (2016). A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem, 11(11), 1117–1121. https://doi.org/10.1002/cmdc.201600182
Molinspiration Cheminformatics. (2006). Molinspiration cheminformatics. Choice Reviews Online, 43(11), 43-6538.
Ferreira, L. L. G., & Andricopulo, A. D. (2019). ADMET modeling approaches in drug discovery. Drug Discovery Today, 24(5), 1157–1165. https://doi.org/10.1016/j.drudis.2019.03.015
Begley, D. J., & Brightman, M. W. (2003). Structural and functional aspects of the blood–brain barrier. In Peptide transport and delivery into the central nervous system (pp. 39–78). Birkhäuser. https://doi.org/10.1007/978-3-0348-8049-7_2.
Organisation for Economic Co-operation and Development. (2014). Guidance document on the validation of (quantitative) structure–activity relationship [(Q)SAR] models (OECD Series on Testing and Assessment No. 69). OECD Publishing. https://doi.org/10.1787/9789264085442-en
Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y. C., Todeschini, R., Consonni, V., Kuz’min, V. E., Cramer, R., Benigni, R., Yang, C., Rathman, J., Terfloth, L., Gasteiger, J., Richard, A., & Tropsha, A. (2014). QSAR modeling: Where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977–5010. https://doi.org/10.1021/jm4004285
Grewal, S., Deswal, G., Grewal, A. S., & Guarve, K. (2025). Molecular dynamics simulations: Insights into protein and protein-ligand interactions. Advances in Pharmacology, 103, 139–162. https://doi.org/10.1016/bs.apha.2025.01.007
Ormeño, F., & General, I. J. (2024). Convergence and equilibrium in molecular dynamics simulations. Communications Chemistry, 7, Article 26. https://doi.org/10.1038/s42004-024-01114-5
Jose, J., Varughese, J. K., Parvez, M. K., & Mathew, T. V. (2024). Probing the inhibition of MAO-B by chalcones: An integrated approach combining molecular docking, ADME analysis, MD simulation, and MM-PBSA calculations. Journal of Molecular Modeling, 30, Article 103. https://doi.org/10.1007/s00894-024-05889-1
Is, Y. S., Durdagi, S., Aksoydan, B., & Yurtsever, M. (2018). Proposing novel MAO-B hit inhibitors using multidimensional molecular modeling approaches and application of binary QSAR models for prediction of their therapeutic activity, pharmacokinetic and toxicity properties. ACS Chemical Neuroscience, 9(7), 1768–1782. https://doi.org/10.1021/acschemneuro.8b00095

Details

Primary Language

English

Subjects

Enzymes

Journal Section

Research Article

Authors

Arzu Öztürk Kesebir ^*
0000-0003-2603-7509
Türkiye

Publication Date

October 27, 2026

Submission Date

January 11, 2026

Acceptance Date

October 20, 2026

Published in Issue

Year 2026 Volume: 47 Number: 5

DOI

https://doi.org/10.17776/csj.1860936

IZ

https://izlik.org/JA86WJ26BM

APA

Öztürk Kesebir, A. (2026). An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease. Cumhuriyet Science Journal, 47(5), 981-995. https://doi.org/10.17776/csj.1860936

AMA

1.Öztürk Kesebir A. An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease. CSJ. 2026;47(5):981-995. doi:10.17776/csj.1860936

Chicago

Öztürk Kesebir, Arzu. 2026. “An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease”. Cumhuriyet Science Journal 47 (5): 981-95. https://doi.org/10.17776/csj.1860936.

EndNote

Öztürk Kesebir A (October 1, 2026) An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease. Cumhuriyet Science Journal 47 5 981–995.

IEEE

[1]A. Öztürk Kesebir, “An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease”, CSJ, vol. 47, no. 5, pp. 981–995, Oct. 2026, doi: 10.17776/csj.1860936.

ISNAD

Öztürk Kesebir, Arzu. “An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease”. Cumhuriyet Science Journal 47/5 (October 1, 2026): 981-995. https://doi.org/10.17776/csj.1860936.

JAMA

1.Öztürk Kesebir A. An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease. CSJ. 2026;47:981–995.

MLA

Öztürk Kesebir, Arzu. “An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease”. Cumhuriyet Science Journal, vol. 47, no. 5, Oct. 2026, pp. 981-95, doi:10.17776/csj.1860936.

Vancouver

1.Arzu Öztürk Kesebir. An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease. CSJ. 2026 Oct. 1;47(5):981-95. doi:10.17776/csj.1860936

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December

An Integrated In Silico Investigation of Novel MAO-B Inhibitors for Parkinson’s Disease

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite